Company: ZVRA
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001434647-25-000011
Chunk: 51

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 1
Chunk 51
---
 — — — 3,115 Issuance of common stock in exchange for consulting services— 75 — — — 75 Issuance of common stock for options exercised or RSUs vested— 1,979 — — — 1,979 Other comprehensive loss— — — — (713)(713)Balance as of March 31, 2025$5 $560,471 $(10,983)$(508,388)$(82)$41,023 Net income— — — 74,707 — 74,707 Stock-based compensation expense— 2,464 — — — 2,464 Issuance of common stock as part of the Employee Stock Purchase Plan— 413 — — — 413 Issuance of common stock for options exercised or RSUs vested1 968 — — — 969 Other comprehensive loss— — — — (2,346)(2,346)Balance as of June 30, 2025$6 $564,316 $(10,983)$(433,681)$(2,428)$117,230 Net loss— — — (544)— (544)Stock-based compensation expense— 2,771 — — — 2,771 Issuance of common stock for options exercised or RSUs vested— 573 — — — 573 Issuance of common stock for stock warrants exercised— 13,123 — — — 13,123 Other comprehensive income— — — — 12 12 Balance as of September 30, 2025$6 $580,783 $(10,983)$(434,225)$(2,416)$133,165 

See accompanying notes to unaudited condensed consolidated financial statements.

7

ZEVRA THERAPEUTICS, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY, CONTINUED

(in thousands)

AdditionalTreasuryOtherTotalCommonPaid-inStock,AccumulatedComprehensiveStockholders'StockCapitalat costDeficitIncome (Loss)EquityBalance as of January 1, 2024$4 $472,664 $(10,983)$(399